Physician profile
Leonides D Bermejo
NPI 1821319989
$3,251.16
in general payments reported to CMS, 2019-2025
31 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $497 · 2021: $671 · 2022: $446 · 2023: $304 · 2024: $531 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $393.76 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $392.71 | 2019-2024 | Rytary, Ongentys, Ongentys 50mg Capsules 30 |
| Novartis Pharmaceuticals Corporation | $307.00 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $300.40 | 2019-2024 | Ultomiris |
| Abbvie INC. | $285.70 | 2021-2025 | Qulipta, Ubrelvy |
| Sunovion Pharmaceuticals INC. | $246.30 | 2019-2022 | |
| Biogen, INC. | $162.98 | 2019-2024 | Spinraza, Qalsody |
| Allergan, INC. | $152.84 | 2020 | |
| Emd Serono, INC. | $145.91 | 2019-2024 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $124.47 | 2021 | |
| Genzyme Corporation | $110.56 | 2019-2024 | |
| Sk Life Science, INC. | $105.63 | 2023-2024 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $63.16 | 2019-2023 | Ajovy |
| Lilly USA, LLC | $60.30 | 2020-2024 | Reyvow, Emgality, Amyvid |
| Mallinckrodt Enterprises LLC | $56.47 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $55.07 | 2022-2025 | Rystiggo |
| Biohaven Pharmaceutical Holding Company LTD. | $53.93 | 2022 | |
| Lundbeck LLC | $25.31 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.96 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.86 | 2019 | |
| Livanova USA, INC. | $17.77 | 2019 | |
| Argenx US, INC. | $17.77 | 2023 | Vyvgart |
| Tanabe Pharma America, INC. | $17.77 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.49 | 2019 | |
| Ge Healthcare | $16.17 | 2022 | |
| Philips North America LLC | $16.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.22 | 2019 | |
| Neurelis, INC. | $15.13 | 2021 | |
| Pfizer INC. | $14.13 | 2019 | |
| Kyowa Kirin, INC. | $13.39 | 2022 | |
| Genentech USA, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonides Bermejo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.